{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:58:29Z","timestamp":1790247509365,"version":"4.1.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The unfavorable clinical evolution in indolent non-Hodgkin lymphomas suggests defective control of neoplastic growth by the immune system. To address this issue, we evaluated phenotype, function, and maturation profile of CD4+ and CD8+ T cells from peripheral-blood, lymph nodes, or bone marrow of patients with B-cell non-Hodgkin lymphoma (NHL) at diagnosis. T cells from these patients frequently showed an activated but apoptosis-prone phenotype with low frequency of tumor-reactive T cells showing a TH2\/Tc2 functional profile in the response to autologous tumor. In peripheral blood or in lymph nodes and bone marrow, and, in comparison to healthy donors, patients' T cells showed a skewed differentiation toward Tnaive and Tcentral memory stages, with low expression of granzyme B and perforin. T-cell culture with autologous tumor in the presence of IL-2, IL-15, and autologous bone marrow\u2013derived cells led to massive T-cell expansion and to differentiation of cytotoxic factor+ CD8+ T cells releasing IFN-\u03b3 and killing autologous B-cell tumor in an HLA-class I\u2013restricted fashion. These results suggest impaired T-cell differentiation to effector stage in patients with B-cell NHL, but indicate that T-cell responsiveness to \u03b3c cytokines is retained, thus allowing to promote generation of antitumor T cells for immune intervention.<\/jats:p>","DOI":"10.1182\/blood-2005-06-2234","type":"journal-article","created":{"date-parts":[[2005,9,9]],"date-time":"2005-09-09T00:43:51Z","timestamp":1126226631000},"page":"602-609","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Skewed T-cell differentiation in patients with indolent non-Hodgkin lymphoma reversed by ex vivo T-cell culture with \u03b3c cytokines"],"prefix":"10.1182","volume":"107","author":[{"given":"Andrea","family":"Anichini","sequence":"first","affiliation":[{"name":"From the Human Tumor Immunobiology Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; the \u201cCristina Gandini\u201d Bone Marrow Transplantation Unit, Department of Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; and the Department of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Mortarini","sequence":"additional","affiliation":[{"name":"From the Human Tumor Immunobiology Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; the \u201cCristina Gandini\u201d Bone Marrow Transplantation Unit, Department of Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; and the Department of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Romagnoli","sequence":"additional","affiliation":[{"name":"From the Human Tumor Immunobiology Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; the \u201cCristina Gandini\u201d Bone Marrow Transplantation Unit, Department of Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; and the Department of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Baldassari","sequence":"additional","affiliation":[{"name":"From the Human Tumor Immunobiology Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; the \u201cCristina Gandini\u201d Bone Marrow Transplantation Unit, Department of Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; and the Department of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Cabras","sequence":"additional","affiliation":[{"name":"From the Human Tumor Immunobiology Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; the \u201cCristina Gandini\u201d Bone Marrow Transplantation Unit, Department of Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; and the Department of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Carlo-Stella","sequence":"additional","affiliation":[{"name":"From the Human Tumor Immunobiology Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; the \u201cCristina Gandini\u201d Bone Marrow Transplantation Unit, Department of Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; and the Department of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Gianni","sequence":"additional","affiliation":[{"name":"From the Human Tumor Immunobiology Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; the \u201cCristina Gandini\u201d Bone Marrow Transplantation Unit, Department of Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; and the Department of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Di Nicola","sequence":"additional","affiliation":[{"name":"From the Human Tumor Immunobiology Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; the \u201cCristina Gandini\u201d Bone Marrow Transplantation Unit, Department of Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; and the Department of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111817134650400_REF1","doi-asserted-by":"crossref","unstructured":"Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. Lancet Oncol. 2004;5: 341-353.","DOI":"10.1016\/S1470-2045(04)01490-1"},{"key":"2019111817134650400_REF2","doi-asserted-by":"crossref","unstructured":"Chiorazzi N, Rai KR, Ferrarini M. Mechanisms of disease. Chronic lymphocytic leukemia. New Engl J Med. 2005;352: 804-815.","DOI":"10.1056\/NEJMra041720"},{"key":"2019111817134650400_REF3","doi-asserted-by":"crossref","unstructured":"Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346: 1937-1947.","DOI":"10.1056\/NEJMoa012914"},{"key":"2019111817134650400_REF4","doi-asserted-by":"crossref","unstructured":"Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002;99: 1517-1526.","DOI":"10.1182\/blood.V99.5.1517"},{"key":"2019111817134650400_REF5","doi-asserted-by":"crossref","unstructured":"Medeiros LJ, Picker LJ, Gelb AB, et al. Numbers of host \u201chelper\u201d T cells and proliferating cells predict survival in diffuse small-cell lymphomas. J Clin Oncol. 1989;7: 1009-1017.","DOI":"10.1200\/JCO.1989.7.8.1009"},{"key":"2019111817134650400_REF6","doi-asserted-by":"crossref","unstructured":"Ansell SM, Stenson M, Habermann TM, Jelinek DF, Witzig TE. CD4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol. 2001;19: 720-726.","DOI":"10.1200\/JCO.2001.19.3.720"},{"key":"2019111817134650400_REF7","doi-asserted-by":"crossref","unstructured":"Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351: 2159-2169.","DOI":"10.1056\/NEJMoa041869"},{"key":"2019111817134650400_REF8","doi-asserted-by":"crossref","unstructured":"Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol. 2004;22: 4717-4724.","DOI":"10.1200\/JCO.2004.06.003"},{"key":"2019111817134650400_REF9","doi-asserted-by":"crossref","unstructured":"Trojan A, Schultze JL, Witzens M, et al. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med. 2000;6: 667-672.","DOI":"10.1038\/76243"},{"key":"2019111817134650400_REF10","doi-asserted-by":"crossref","unstructured":"Grube M, Rezvani K, Wiestner A, et al. Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies. Clin Cancer Res. 2004;10: 1047-1056.","DOI":"10.1158\/1078-0432.CCR-03-0075"},{"key":"2019111817134650400_REF11","doi-asserted-by":"crossref","unstructured":"Andersen MH, Svane IM, Kvistborg P, et al. Immunogenicity of Bcl-2 in patients with cancer. Blood. 2005;105: 728-734.","DOI":"10.1182\/blood-2004-07-2548"},{"key":"2019111817134650400_REF12","doi-asserted-by":"crossref","unstructured":"Mayr C, Bund D, Schlee M, et al. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. Blood. 2005;105: 1566-1573.","DOI":"10.1182\/blood-2004-04-1233"},{"key":"2019111817134650400_REF13","doi-asserted-by":"crossref","unstructured":"Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22: 745-63.","DOI":"10.1146\/annurev.immunol.22.012703.104702"},{"key":"2019111817134650400_REF14","doi-asserted-by":"crossref","unstructured":"Anichini A, Molla A, Mortarini R, et al. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med. 1999;190: 651-667.","DOI":"10.1084\/jem.190.5.651"},{"key":"2019111817134650400_REF15","doi-asserted-by":"crossref","unstructured":"Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84: 1361-1392.","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"2019111817134650400_REF16","unstructured":"Pietra G, Mortarini R, Parmiani G, Anichini A. Phases of apoptosis of melanoma cells, but not of normal melanocytes, differently affect maturation of myeloid dendritic cells. Cancer Res. 2001;61: 8218-8226."},{"key":"2019111817134650400_REF17","unstructured":"Di Nicola M, Napoli S, Anichini A, et al. Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells induced by staurosporine or vaccinia virus infection. Haematologica. 2003;88: 1396-1404."},{"key":"2019111817134650400_REF18","doi-asserted-by":"crossref","unstructured":"Anichini A, Scarito A, Molla A, Parmiani G, Mortarini R. Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common gamma-chain cytokines. J Immunol. 2003;171: 2134-2141.","DOI":"10.4049\/jimmunol.171.4.2134"},{"key":"2019111817134650400_REF19","doi-asserted-by":"crossref","unstructured":"Maccalli C, Farina C, Sensi M, Parmiani G, Anichini A. TCR beta-chain variable region-driven selection and massive expansion of HLA-class I-restricted antitumor CTL lines from HLA-A*0201+ melanoma patients. J Immunol. 1997;158: 5902-5913.","DOI":"10.4049\/jimmunol.158.12.5902"},{"key":"2019111817134650400_REF20","doi-asserted-by":"crossref","unstructured":"Pupa SM, Argraves SW, Forti S, et al. Immunological and pathobiological roles of fibulin-1 in breast cancer. Oncogene2004;23: 2153-2160.","DOI":"10.1038\/sj.onc.1207323"},{"key":"2019111817134650400_REF21","doi-asserted-by":"crossref","unstructured":"Di Nicola M, Carlo-Stella C, Mortarini R, et al. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma. Clin Cancer Res. 2004;10: 5381-5390.","DOI":"10.1158\/1078-0432.CCR-04-0602"},{"key":"2019111817134650400_REF22","doi-asserted-by":"crossref","unstructured":"Fellenberg K, Hauser NC, Brors B, Neutzner A, Hoheisel JD, Vingron M. Correspondence analysis applied to microarray data. Proc Natl Acad Sci U S A. 2001;98: 10781-10786.","DOI":"10.1073\/pnas.181597298"},{"key":"2019111817134650400_REF23","doi-asserted-by":"crossref","unstructured":"Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002;8: 379-385.","DOI":"10.1038\/nm0402-379"},{"key":"2019111817134650400_REF24","doi-asserted-by":"crossref","unstructured":"Agrawal S, Marquet J, Delfau-Larue MH, et al. CD3 hyporesponsiveness and in vitro apoptosis are features of T cell from both malignant and non malignant secondary lymphoid organs. J Clin Invest. 1998;102: 1715-1723.","DOI":"10.1172\/JCI3784"},{"key":"2019111817134650400_REF25","doi-asserted-by":"crossref","unstructured":"Groneberg C, Pickartz T, Binder A, et al. Clinical relevance of CD95 (Fas-Apo-1) on T cells of patients with B-cell chronic lymphocytic leukemia. Exp Hematol. 2003;31: 682-685.","DOI":"10.1016\/S0301-472X(03)00109-7"},{"key":"2019111817134650400_REF26","doi-asserted-by":"crossref","unstructured":"Hjalmar V, Hsat R, Kimby E. Cell surface expression of CD25, CD54 and CD95 on B- and T-cells in chronic lymphocytic leukaemia in relation to trisomy12, atypical morphology and clinical course. Eur J Haematol. 2002;68: 127-134.","DOI":"10.1034\/j.1600-0609.2002.01515.x"},{"key":"2019111817134650400_REF27","doi-asserted-by":"crossref","unstructured":"Tinhofer I, Marschitz I, Kos M, et al. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-17CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. Blood1998;91: 4273-4281.","DOI":"10.1182\/blood.V91.11.4273"},{"key":"2019111817134650400_REF28","doi-asserted-by":"crossref","unstructured":"Silvestris F, Tucci M, Cafforio P, Dammacco F. Fas-L up-regulation by highly malignant myeloma plasma cells. Blood. 2001;97: 1155-1164.","DOI":"10.1182\/blood.V97.5.1155"},{"key":"2019111817134650400_REF29","doi-asserted-by":"crossref","unstructured":"Verbeke CS, Wenthe U, Grobholz R, Zentgraf H. Fas ligand expression in Hodgkin lymphoma. Am J Surg Pathol. 2001;25: 388-394.","DOI":"10.1097\/00000478-200103000-00014"},{"key":"2019111817134650400_REF30","doi-asserted-by":"crossref","unstructured":"Grullich C, Richter M, Exner S, Finke J. Fas ligand is not constitutively expressed in low-grade B-cell lymphoma and B-lymphoblastoid cells. Eur J Haematol. 2003;71: 184-188.","DOI":"10.1034\/j.1600-0609.2003.00117.x"},{"key":"2019111817134650400_REF31","doi-asserted-by":"crossref","unstructured":"Dukers DF, Oudejans JJ, Vos W, ten Berge RL, Meijer CJ. Apoptosis in B-cell lymphomas and reactive lymphoid tissues always involves activation of caspase 3 as determined by a new in situ detection method. J. Pathol. 2002;196: 307-315.","DOI":"10.1002\/path.1046"},{"key":"2019111817134650400_REF32","doi-asserted-by":"crossref","unstructured":"Kim JW, Wieckwski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL. Fas-ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res. 2005;11: 1010-1020.","DOI":"10.1158\/1078-0432.1010.11.3"},{"key":"2019111817134650400_REF33","doi-asserted-by":"crossref","unstructured":"Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfatti M. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med. 1992;176: 1319-1326.","DOI":"10.1084\/jem.176.5.1319"},{"key":"2019111817134650400_REF34","doi-asserted-by":"crossref","unstructured":"Kay NE, Han L, Bone N, Williams G. Interleukin-4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: impact on clonal B-cell apoptosis. Br J Haematol. 2001;112: 760-767.","DOI":"10.1046\/j.1365-2141.2001.02605.x"},{"key":"2019111817134650400_REF35","doi-asserted-by":"crossref","unstructured":"Podhorecka M, Dmoszynska A, Rolinski J, Wasik E. T type1\/type 2 subsets balance in B-cell chronic lymphocytic leukemia: three color flow cytometry analysis. Leuk Res. 2002;26: 657-660.","DOI":"10.1016\/S0145-2126(01)00194-1"},{"key":"2019111817134650400_REF36","doi-asserted-by":"crossref","unstructured":"Fowler-Mainou T, Proctor SJ, Miller S, Dickinson AM. Expression and production of interleukin-4 in B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2001;42: 689-698.","DOI":"10.3109\/10428190109099331"},{"key":"2019111817134650400_REF37","doi-asserted-by":"crossref","unstructured":"Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4: 540-550.","DOI":"10.1038\/nrc1388"},{"key":"2019111817134650400_REF38","doi-asserted-by":"crossref","unstructured":"Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med. 2000;192: 755-760.","DOI":"10.1084\/jem.192.5.755"},{"key":"2019111817134650400_REF39","doi-asserted-by":"crossref","unstructured":"Clementi R, Locatelli F, Dupre L, et al. A proportion of patients with lymphoma may harbor mutations of the perforin gene. Blood. Prepublished on February 22, 2005, as DOI 10.1182\/blood-2004-04-1477. (Now available as Blood. 2005;105: 4424-4428).","DOI":"10.1182\/blood-2004-04-1477"},{"key":"2019111817134650400_REF40","doi-asserted-by":"crossref","unstructured":"Clementi R, Dagna L, Dianzani U, et al. Inherited perforin and Fas mutations in a patient with autoimmune lymphoproliferative syndrome and lymphoma. N Engl J Med. 2004;351: 1419-1424.","DOI":"10.1056\/NEJMoa041432"},{"key":"2019111817134650400_REF41","doi-asserted-by":"crossref","unstructured":"Urosevic M, Dummer R. HLA-G and IL-10 expression in human cancer-different stories with the same message. Semin Cancer Biol. 2003;13: 337-342.","DOI":"10.1016\/S1044-579X(03)00024-5"},{"key":"2019111817134650400_REF42","doi-asserted-by":"crossref","unstructured":"Dorfman DM, Schultze JL, Shahsafaei A, et al. In vivo expression of B7\u20131 and B7\u20132 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood. 1997;90: 4297-4306.","DOI":"10.1182\/blood.V90.11.4297"},{"key":"2019111817134650400_REF43","unstructured":"Orsini E, Guarini A, Chiaretti S, Mauro FR, Foa R. The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. Cancer Res. 2003;63: 4497-4506."},{"key":"2019111817134650400_REF44","doi-asserted-by":"crossref","unstructured":"Tsukishiro T, Donnenberg AD, Whiteside TL. Rapid turnover of the CD8(+)CD28(\u2013) T-cell subset of effector cells in the circulation of patients with head and neck cancer. Cancer Immunol Immunother. 2003;52: 599-607.","DOI":"10.1007\/s00262-003-0395-6"},{"key":"2019111817134650400_REF45","doi-asserted-by":"crossref","unstructured":"Kuss I, Donnenberg AD, Gooding W, Whiteside TL. Effector CD8+CD45RO\u2013CD27\u2013 T cells have signalling defects in patients with squamous cell carcinoma of the head and neck. Br J Cancer. 2003;88: 223-230.","DOI":"10.1038\/sj.bjc.6600694"},{"key":"2019111817134650400_REF46","doi-asserted-by":"crossref","unstructured":"Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A. 2004;101: 14639-14645.","DOI":"10.1073\/pnas.0405730101"},{"key":"2019111817134650400_REF47","doi-asserted-by":"crossref","unstructured":"Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med. 2004;200: 1623-1633.","DOI":"10.1084\/jem.20040890"},{"key":"2019111817134650400_REF48","doi-asserted-by":"crossref","unstructured":"Gluck WL, Hurst D, Yuen A, et al. Phase I studies of interleukin (IL-2) and rituximab in B-cell non Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res. 2004;10: 2253-2264.","DOI":"10.1158\/1078-0432.CCR-1087-3"},{"key":"2019111817134650400_REF49","doi-asserted-by":"crossref","unstructured":"Eisenbeis CF, Grainger A, Fischer B, et al. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study. Clin Cancer Res. 2004;10: 6101-6110.","DOI":"10.1158\/1078-0432.CCR-04-0525"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/2\/602\/1281027\/zh800206000602.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/2\/602\/1281027\/zh800206000602.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T11:33:30Z","timestamp":1683200010000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/2\/602\/131484\/Skewed-Tcell-differentiation-in-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,15]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,1,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-06-2234","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,15]]}}}